Home India Ministry of Health and Family Welfare NSQ May 2024 CDSCO Labs...
Date: 2024-06-20 Category: Not Applicable State: Union Government Country: India

NSQ May 2024 CDSCO Labs

Issued by Ministry of Health and Family Welfare · Central Drugs Standard Control Organization

Research with AI Agent Chat with Document Generate Summary Translate Helpful Share Add to Project Create Task

Executive Summary & Key Takeaways

What it means

  • This gazette notification is a list of drugs, medical devices, and cosmetics that have been declared as Not of Standard Quality (NSQ) for the month of May 2024 by the Central Drugs Standard Control Organization (CDSCO) and various Central and Regional Drugs Testing Laboratories.
  • The list includes the name of the drug/medical device/cosmetic, batch number, manufacturing and expiry dates, manufacturer, the reason for being declared NSQ, and the reporting laboratory.

Key Changes

  • A total of 39 products are listed as Not of Standard Quality (NSQ).
  • The reasons for NSQ include failure to meet manufacturer's specifications, failure to conform to IP/USP standards with respect to tests such as Assay, Dissolution, Related Substances, Clarity of Solution, Particulate Matter, pH, Diethylene Glycol content, Extractable Volume, Free Dexamethasone, and Sterility.
  • Several manufacturers are listed, including Priya Life Science, Scott-Edil Pharmacia Ltd., ELFOS LABORATORIES, Daxin Pharmaceuticals Pvt. Ltd., Esquire Drug House, AK Krishna Pharma Pvt.Ltd., Skymap Pharmaceuticals Pvt. Ltd., RADICALS PHARMA PVT. LTD., WINGS BIOTECH LLP, Broad Injectables, M/s. Navkar Lifesciences, Pace Biotech, M/s. Vivek Pharmachem (India) Ltd., M/s Nandani Medical Laboratories Pvt. Ltd., SAI Parenterals Limited, BIOALTUS PHARMACEUTICALS PRIVATE LIMITED, Healers Lab, VVPB Pharmaceuticals Pvt. Ltd., ZEE LABORATORIES LTD., M/s.Konis Pharmaceuticals, ASKON HEALTH CARE, Bajaj Healthcare Ltd., Rivpra Formulation Pvt.Ltd., M/s. Shine Pharmaceuticals Limited, Technica Lab & Pharma Pvt.Limited, Galpha Laboratories Limited, SVP LIFE SCIENCES, Alliaance Biotech, Unimark Healthcare Ltd., Pharmaroots Healthcare, USV Private Limited, Captab Biotec, Life Max Cancer Laboratories, Integrated Laboratories.
  • The listed products failed quality tests conducted by Central Drugs Laboratories in Kolkata, Hyderabad, and Mumbai, as well as Regional Drugs Testing Laboratories in Chandigarh and Guwahati.
  • One sample of Levosalbutamol Sulphate, Ambroxol HCL, Guaiphenesin Syrup was found to contain 0.0071 % w/v Ethylene glycol.

Impact Analysis

Manufacturers

  • Action Item: Immediately review manufacturing processes and quality control procedures for all listed products. Implement CAPA and communicate these to CDSCO.

Consumers/Patients

  • Action Item: Ensure that internal teams are aware of the listed batch numbers and products. Remove any such products from our supply chain.

Pharmacies/Distributors

  • Action Item: Verify the authenticity and quality of products from listed manufacturers.

Regulatory Agencies (CDSCO)

  • Action Item: Enhance collaboration with state drug controllers to ensure effective monitoring and enforcement.

Key Entities Referenced

CDSCO: Central Drugs Standard Control Organization, the national regulatory body for pharmaceuticals and medical devices in India. IP: Indian Pharmacopoeia, the official book of standards for drugs manufactured and/or marketed in India. USP: United States Pharmacopeia, a pharmacopeia for the United States. Drugs and Cosmetics Act, 1940: The Drugs and Cosmetics Act, 1940 is an Act of the Parliament of India which regulates the import, manufacture, distribution and sale of drugs and cosmetics. Central Drugs Laboratory, Kolkata: A Central Drugs Laboratory that tests drugs and publishes results. Central Drugs Testing Laboratory, Hyderabad: A Central Drugs Laboratory that tests drugs and publishes results. Central Drugs Testing Laboratory, Mumbai: A Central Drugs Laboratory that tests drugs and publishes results. Regional Drugs Testing Laboratory, Chandigarh: A Regional Drugs Testing Laboratory that tests drugs and publishes results. Regional Drugs Testing Laboratory, Guwahati: A Regional Drugs Testing Laboratory that tests drugs and publishes results.
Official Source Record View Original Source →
See Full Document Text
NOT OF STANDARD QUALITY ALERT FOR THE MONTH OF MAY – 2024. A. CDSCO/Central Laboratories S.No Name of Batch Date of Date of Manufactured By NSQ Result Reported by Drugs/medical No. Manufactur Expiry CDSCO Laboratory device/cosmetics e 1. Terbutaline VS16010 01-01-2024 01-12-2026 Priya Life Science,174-A, The sample does not Central Drugs Sulfate,Bromhexin 175,Siddhi Industrial conform to Manufacturer's Laboratory, Kolkata e Hydrochloride Infrastructure Park, Specification with respect with Guaiphenesin Opp. Waghodia to the Assay of Syrup GIDC, Waghodia Bromhexine Hydrochloride and Terbutaline Sulphate. 2. METOPROLOL GT3J026 01-10-2023 30-09-2025 Scott-Edil The sample does not Central Drugs SUCCINATE PharmaciaLtd.,56, EPIP., conforms to claim as per Laboratory, Kolkata EXTENDED Phase-I, I.P.2022inrespectto the RELEASE Jharmajri,Baddi, Test of Dissolution TABLETS IP Distt.Solan-173 205, (1Hr),Dissolution(4 Hours) (H.P.),INDIA 3. Cuftin COUGH ECT- 01-09-2023 31-08-2025 ELFOS The sample does not RDTL , Chandigarh LINCTUS 2421 LABORATORIES,at conforms to claim as per :F-54,M.I.Area, JAIPUR- Patent and Proprietary in 17 respect to the Assay of Sodium Citrate 4. CefuroximeAxetil DB23030 01-12-2023 30-11-2025 Daxin Pharmaceuticals The sample does not Central Drugs Tablets IP 4 Pvt.Ltd.,PlotNo 121-122 conforms to claim as per IP Laboratory, Kolkata EPIP, Jharmajri Phase 1, 2022in respect to the Test Teh. Baddi, Distt. of Dissolution of Solan (H.P.) - 174103 Cefuroxime Axetil equivalent to Cefuroxime 5. LevosalbutamolSul 5346 07-03-2024 04-02-2026 Esquire Drug House,138, The sample does not Central Drugs phate,AmbroxolHC GIDC, Estate,Wadhwan conform to claim as per Laboratory, Kolkata L,Guaiphenesin City, District Schedule V of Drugs & Syrup Cosmetics Act with respect 1 | Pa g eSurendranagar 363035 to Assay of (Gujarat) Levosalbutamol Sulphate Equivalent to Levosalbutamol. NB:The sample does not give positive test for Diethylene glycol and is found to contain 0.0071 % w/v Ethylene glycol; (Limit NMT 0.1% w/v, Method: GC, Ref: USP under the monograph of Propylene glycol,) 6. Acetylsalicylic Acid JTN23- 05-07-2023 03-06-2026 AK Krishna Pharma Sample does not conforms Central Drugs Tablets 75 mg 211 Pvt.Ltd.,Plot No. to IP with respect to test for Laboratory, Kolkata 68, 69 &82,83 Dissolution. Sector-6A, Sidcul, IIE, Dist. Haridwar, Uttarakhand, India. 7. LactuloseSolution GA2312 02-11-2023 07-10-2025 Skymap Pharmaceuticals The sample does not Central Drugs U.S.P. 7 Pvt. Ltd.,B-3, Dev conforms to claim as per Laboratory, Kolkata Bhoomi Industrial Estate, U.S.P.in respect to the PuhanaIqbalpur Road, Assay. Roorkee-247667 8. Terbutaline 23D-20 01-04-2023 31-03-2025 RADICALS The sample does not RDTL, Chandigarh Sulphate, PHARMAPVT. LTD.,194, conforms to claim as per Bromhexine Mile Patent and Proprietary Hydrochloride, Stone, Ambala- Delhi (RDTL/MS/3286)in Guaiphenesinand Highway, respect to the Assay of Menthol Syrup Shahpur,Ambala Cantt- Terbutaline Sulphate, 133 004 Bromhexine (Hry.) Hydrochloride 9. PRDT- 01-11-2022 31-10-2024 WINGSBIOTECH LLP,43 The sample does not RDTL, Chandigarh Prednisolone 1007 & 44, conforms to claim as per IP TabletsIP10mg 2018 and Addendum 2021 2 | Pa g eHPSIDC,Industrial Area, in respect to the Assay of Baddi - 173205 (H.P.) Prednisolone 10. Mecobalamin, DBIS- 02-11-2023 08-10-2025 Broad Injectables,PlotNo. The sample does not Central Drugs AlphaLipoicAcid, 8591 51-52, Ind. Area conforms to claim as per Laboratory, Kolkata Pyridoxine TahliwalDistt. Una Schedule V of Drugs and Hydrochlorideand 174301 (H.P.) Cosmetics Act with respect Folic Acid Soft to the Assay/content of Gelatin Capsules Mecobalamin and PyridoxineHydrochloride 11. TELMISARTAN TE3016A 01-05-2023 30-04-2025 M/s. The sample received CDTL, Hyderabad ANDAMLODIPINE NavkarLifesciences,Plot DOES NOT CONFORM TABLETS IP No. 76, LodhiMajra, toI.P.2022Specification Industrial Area, Baddi, with respect to the test Distt. parameters Dissolution Solan (H.P.) and Assay of Amlodipine Besylate equivalent to Amlodipinecontentonly. CDTLHREPORTNO.: CDTLH/1510/F- 1068/2023-24 12. Cefoperazone& B- 01-01-2023 02-12-2024 Pace Biotech, Surajpur, The sample does not Central Drugs Sulbactam for 22680D Paonta Sahib, Dist- conforms to claim as per Laboratory, Kolkata Injection Sirmour (H.P)- 173001 The Schedule V of The Drugs and Cosmetics Act,1940withrespectto the Test for 'Clarity of solution' and' Particulate matter' 13. Cefotaxime CTI2308 08-08-2023 07-01-2025 M/s. Vivek Pharmachem The sample does not Central Drugs InjectionIP500mg 1 (India) Ltd., NH-8, conforms to I.P. with Laboratory, Kolkata Chimanpura, Amer, respect to the Test for Jaipur-303 102 INDIA 'Related Substances', 'Particulate matter' and 'Clarity of solution' 3 | Pa g e14. Dexamethasone DSA123 06-07-2023 04-06-2025 M/s Nandani Medical The sample does not Central Drugs SodiumPhosphate 13 Laboratories Pvt. conforms to IP with respect Laboratory, Kolkata Injection I.P Ltd.,,221/5,Bicholi Hapsi, to Assay/ content of Kanadia Road, Indore Dexamethasone Phosphate 15. Amoxycillin&Potas 23AP04 03-05-2023 02-04-2025 SAI Parenterals The sample does not Central Drugs sium Clavulanate Limited,,D1&D4, Survey conforms to claim as per Laboratory, Kolkata InjectionIP1.2gm No.280,Phase-V, IDA, I.P. 2022 in respect to the Jeedimetla, Hyderabad, Test of Clarity of solution 500055, TS and Assay of Potassium Clavulanate calculated as Clavulanic Acid 16. TELMISARTAN BD23178 01-12-2023 30-11-2025 BIOALTUS NOTE: THE SAMPLE CDTL, Hyderabad AND 0H PHARMACEUTICA LS RECEIVED DOES NOT METOPROLOL PRIVATE LIMITED,(A CONFORM TO SUCCINATE WHO GMP CERTIFIED MANUFACTURERS (EXTENDED COMPANY) At: 19- SPECIFICATION WITH RELEASE) 20, DIC, Ind. Area, Baddi, RESPECT TO THE TEST TABLETS Distt. Solan, (H.P.) FOR DISSOLUTION FOR 173205 THE CONTENT OF METOPROLOL SUCCINATE EQUIVALENT TO METOPROLOL TARTRATE(EXTENDED RELEASE) AT THE FINAL TEST TIME (20th HOUR) OF L1+L2+L3 LEVEL ONLY. CDTLHREPORTNO.: CDTLH/1527/F- 17. Pantoprazole PAA-507 01-06-2023 31-05-2025 Healers Lab, Unit II, Plot The sample Does not RDTL, Guwahati Tablets I.P.. No. 33, H.P.S.I.D.C., complies conforms to Manufacturer Specification 4 | Pa g eExtn., Baddi, Distt.Solan with respect to the above (H.P.) tests only. 18. Pantoprazole PAA-507 01-06-2023 31-05-2025 Healers Lab, Unit II,Plot The sample Does not RDTL, Guwahati Tablets I.P.. No. 33, H.P.S.I.D.C., complies conforms to Extn., Manufacturer Specification Baddi,Distt.Solan (H.P.) with respect to the above tests only. 19. Ambroxol HCl, VDL- 01-07-2022 30-06-2024 VVPB The sample does not RDTL, Chandigarh Levosalbutamoland 1240 Pharmaceuticals Pvt. conforms to claim as per Guaiphenesin Ltd.,Kh. No. Patent and Proprietary in Syrup 114, Vill. respect to the Test of Damowala, P.O. Diethylene Glycol (DEG) Barotiwala, Baddi, and Assay of Ambroxol Distt. Solan (H.P.) Hydrochloride 20. Dexamethasone 323-885 03-08-2023 09-07-2025 ZEE LABORATORIES The sample does not Central Drugs Sodium Phosphate LTD.,Behind47, Industrial conforms to IP with respect Laboratory, Kolkata Injection I.P. Area, Paonta Sahib- to test for "Free (8mg/2ml) 173025 Dexamethasone", "Particulate matter,", "Extractable volume" ,"Assay of Dexamethasone Sodium Phosphate calculated as Dexamethasone Phosphate" and is also not of standard quality for the reason stated under "Description". 21. Dexamethasone DX-2305 05-05-2023 04-04-2025 M/s.Konis The sample does not Central Drugs Sodiumphosphate Pharmaceuticals, conforms to claim as per Laboratory, Kolkata Injection IP Krishna Nagar - 522502 IP2022 in respect to the (A.P.) Test of Description and Particulate matter 22. Paracetamol 500 PAR-31 01-08-2023 31-07-2026 ASKON HEALTH The sample Does not RDTL, Guwahati mg. Tablets CARE,11-B, Complies conforms to 5 | Pa g eINDUSTRIAL I.P. with respect to the AREA, MAXI above tests only. ROAD,UJJAIN- 456010(M.P.) 23. Ofloxacin AD24059 01-04-2024 31-03-2026 Skymap Pharmaceuticals Note: the sample received CDTL, Hyderabad Ornidazole Tablets Pvt. Ltd.,(A WHO- does not IP GMP Certified conformtoi.p.2022 Company)B-3,Dev specification with respect Bhoomi Industrial Estate, to the test for dissolution PuhanaIqbalpur Road, for the content of ofloxacin Roorkee-247667 and ornidazole ( s1, s2 and s3 level) only. Cdtlh report no.: cdtlh/0131/f- 24. Vildagliptinand VMC04G 01-10-2023 30-09-2025 Bajaj Healthcare The sample does not Central Drugs Metformin 23A Ltd.,R.S.No.1818, conform to IP with respect Laboratory, Kolkata Hydrochloride Manjusar – Savli Road, to the test for Dissolution Tablets IP At & Post- Manjusar, Tal. and Assay of Vildagliptin. 50mg/1000mg Savli, Dist. Vadodara- 391775. 25. Amoxycillin & TCV- 01-03-2023 28-02-2025 Rivpra The sample does not RDTL, Guwahati Potassium 2303003 FormulationPvt.Ltd.,Plot conform to I.P. with respect Clavulanate No.8, Sector-6A, I.I.E. to the test for Assay. Tablets I.P.. SIDCUL, Haridwar- 249 403 (U.K.) 26. Clonazepam 04L23T0 06-12-2023 04-11-2026 M/s. Shine The sample does not Central Drugs TabletsI.P.0.5mg 3 Pharmaceuticals conforms to claim as per IP Laboratory, Kolkata Limited,, PlotNo. 132, in respect to Karjan- Vermardi Road, The Test of Related Juni Jitherdi, Ta. Substances Karjan-391240, Dist: Vadodara, (Gujarat). 27. Metronidazole TC- 03-03-2023 04-02-2025 Technica Lab & Pharma The sample does not Central Drugs Extended Release 060323 Pvt.Limited, Plot No. conform to U.S.P with Laboratory, Kolkata 6 | Pa g eTablets USP 600 100, Sector- 7, IIE, respect to the test of MG SIDCUL ,Haridwar, Dissolution. Uttarakhand 28. Diclofenac Sodium RCT230 09-06-2023 04-02-2026 Galpha Laboratories The sample does not Central Drugs and Paracetamol 50 Limited..,Village - Thana, conforms to claim as per IP Laboratory, Kolkata Tablets IP Baddi, Himachal in respect to the Test of Pradesh- 173 205.. Description 29. Atropine Sulphate 23UG18 01-07-2023 30-062025 SVP LIFE The sample does not RDTL , Chandigarh Injection IP SCIENCES,C/10-1 conforms to claim as per Sara Industrial Estate, IP2022in respect to the Selaqui, Dehradun Test of pH and Assay of Atropine Sulphate 30. Montelukast ATA-176 01-02-2023 31-01-2025 Alliaance Biotech,,440/3, The sample does not RDTL, Guwahati Sodium & Village Katha, Baddi, conform to I.P. with respect Levocetirizine Distt.Solan (HP) - 173205 to the above tests only. Hydrochloride Tablets 31. Fluconazole UGT233 01-03-2023 28-02-2025 Unimark Healthcare Ltd., The sample received does CDTL, Mumbai Tablets IP (150 38 Plot No.: 24, 25 & 37 not conform to the mg).. Sector 6 A, SIDCUL, I.P.2022 standard with Haridwar - 249403 respect to the test for (Uttarakhand) Related substances. 32. Ceftriaxone 324-166 02-02-2024 07-07-2026 Zee Laboratories The sample does not Central Drugs Injection I.P Limited,,Behind47, complies to claim as per IP Laboratory, Kolkata Industrial Area, Paonta 2022in respect of test for Sahib- 173205. appearance of solution, clarity of solution, particulate matter and sterility (Powder for Injection). 33. Ramipril & PT- 01-07-2023 01-06-2025 PharmarootsHealthcare, The sample received does CDTL,Mumbai Hydrochlorthiazide 31954 Khasra No. 411, Village not conform to the Tablets IP Tipra, P.O. Barotiwala, I.P.2022standardwith Tehsil Baddi,Distt.Solan, respect to the test for H.P. assay of Ramipril. 7 | Pa g eNote:-Other test could not be done due to technical reason 34. GLIPIZIDEAND 4010026 08-11-2023 03-04-2025 USV Private Limited,At : The sample does not CDL, Kolkata METFORMIN B- 249/B-250, IInd conform to claim I.P. with TABLETS IP Stage, Peenya Industrial respect to the test for Estate, Bangalore-560 Dissolution of Glipizide 058 35. Ceftriaxone for DC3011 05-10-2023 09-09-2025 Captab Biotec, Unit- II, The sample does not CDL, Kolkata InjectionI.P.1gm 9 Plot No.125, conforms to I.P. with E.P.I.P. Road, respect to test for Mauja, Jharmajri, Baddi, "Particulate Matter Distt. Solan, H.P. 36. Gentamicin 323-216 03-03-2023 05-02-2025 ZEE LABORATORIES The sample does not CDL, Kolkata Sulphate Injection LTD., Behind 47, Indl. conforms to I.P. with I.P. 2ml Area, Paonta Sahib- respect to the test for 173025 "Particulate matter" and is also not of standard quality for the reason stated under "Description" 37. Calcium 500 mg LMT240 01-03-2023 28-02-2026 Life Max Cancer The sample Does not RDTL, Guwahati withVitaminD3250 263 Laboratories , Plot No. Complies conforms to IU Tablets IP 106 & 106 A, I.P. with respect to the Sector-6A, IIE, SIDCUL, above tests only. Haridwar- 249403 (U.K) 38. Cefixime & DB23005 02-02-2023 01-01-2025 Daxin Pharmaceuticals The sample does not CDL, Kolkata Ofloxacin Tablets 7 Pvt.Ltd.,PlotNo 121-122 conforms to claim as per EPIP, Schedule V of Drugs & Jharmajri Phase1, Teh. Cosmetics Act with respect Baddi, Distt. Solan (H.P.) to the Assay of Cefixime -174103 Trihydrate eq. to anhydrous Cefixime and Assay of Ofloxacin 39. Ceftriaxone C2402- 02-02-2024 05-01-2026 Integrated Laboratories The sample does not Central Drugs Injection IP 02F Pvt. Ltd., Nahan conform to IP with respect Laboratory, Kolkata 8 | Pa g eRoad. Vill. to the Particulate matter, Moginand, Kala Amb, Clarity of Solution and for Distt. Sirmour (H.P.)- the reason stated under 173030 Description 9 | Pa g e

Continue your research